Copy Number–Driven COX19 Promotes Colorectal Cancer Growth and Represents a Potential Therapeutic Target of Olmesartan
Year: 2026
Type: article
Abstract: Background/Aim Colorectal cancer (CRC) is a leading cause of cancer‐related mortality worldwide. This study aimed to identify tumor‐associated genes in CRC and explore potential therapeutic agents by analyzing chromosomal amplification. Methods DNA copy number variation (CNV) and mRNA expression data from The Cancer Genome Atlas (TCGA) and Cancer Cell Line Encyclopedia (CCLE) were analyzed. We focused on cytochrome c oxidase assembly factor 19 (COX19) as a candidate tumor‐associated gene and examined its clinicopathological and prognostic relevance. Single‐cell RNA sequencing and immunohistochemical analyses were performed. Pathway and drug sensitivity analyses were conducted, followed by in vitro validation of candidate compounds. Results COX19, a mitochondrial complex IV assembly factor, was significantly amplified and overexpressed in CRC. High COX19 expression correlated with poor prognosis and was predominantly observed in tumor epithelial cells. Gene set enrichment analysis (GSEA) suggested suppression of apoptosis in COX19 ‐high tumors. Drug sensitivity analysis identified olmesartan as a candidate therapeutic agent. Olmesartan suppressed the proliferative capacity of COX19 ‐overexpressing CRC cells, whereas COX19 knockout reduced sensitivity to olmesartan. Olmesartan also increased miR‐205‐3p expression, and miR‐205‐3p inhibition partially attenuated its antiproliferative effect. Conclusion COX19 may be a tumor‐associated gene linked to tumor progression and poor prognosis in CRC. Olmesartan may represent a potential therapeutic candidate for COX19 ‐high CRC. Its antiproliferative effects may involve miR‐205‐3p, although the underlying mechanism requires further validation.
DOI: 10.1002/ags3.70303
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,350
Awards: 空間的シングルセル解析による大腸腺腫から発がん過程に於ける免疫寛容獲得機構の解明, 前転移ニッチ構成細胞を標的にした大腸がん根治術後再発予防法の確立, 転写産物のロングリード・シーケンスによる食道癌化学放射線療法抵抗性獲得機構の解明, メチル化ctDNAによる大腸がん根治術後再発早期診断の実装的モニタリング法の開発, VISIUMによる乳がん転移阻害剤プロパゲルマニウムによる免疫能賦活化誘導機構の解明, 膵がん微小環境を構築する細胞社会において免疫寛容に寄与するがん代謝機構の解明, G5128248928, 空間的シングルセル解析による食道がん免疫寛容機構の解明とオミクスアプローチ, The Novel approach for Liver Cirrhosis developed by human liver cirrhosis model using iPS technology, G7732826976, G8146946748
OpenAlex ID: W7235990510
